Calcification-resistant biomaterials

• US 6,302,909 B1
• Filed: 07/31/1996
• Issued: 10/16/2001
• Est. Priority Date: 07/31/1996
• Status: Expired due to Fees

• Current Assignee: St Jude Medical Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: St Jude Medical Incorporated (Abbott Laboratories Incorporated)
• Inventors: Ogle, Matthew F., Schroeder, Richard F.
• Primary Examiner(s): Prebilic, Paul B.
• Application Number:
  US08/690,661
• Time in Patent Office: 1,903 Days
• Field of Search: 623/1, 623/2, 623/11, 623/901, 623/1.42, 623/1.45, 623/2.42, 623/916, 623/917, 623/921, 623/925, 8 9/411, 427/2.24, 427/2.25
• US Class Current: 623/1.42
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device
• CPC Class Codes: Y10S 623/925 Natural

Abstract

The invention involves a bioprosthetic article including a biocompatible material having at least one bound exogenous storage structure, the storage structures having collectively greater than about 0.5 mg metal cations per gram of biocompatible material. The calcification inhibitors preferably decrease calcium deposition by greater than 95% relative to untreated tissue. The calcification inhibitors are bonded to the bioprosthetic material preferably at a pH between about 6.0 and 8.5.

Claims

1. A bioprosthetic article comprising a biocompatible material forming at least a portion of said bioprosthetic article and a plurality of exogenous storage structures that are bound to the biocompatible material by covalent bonds, antibody-antigen associations, specific binding protein-receptor associations or enzyme-substrate associations, said exogenous storage structures comprising natural macromolecules selected from the group consisting of proteins, carbohydrates and nucleic acids that are in addition or as an alternative to any naturally occurring structures and said exogenous storage structures collectively having greater than about 0.5 mg metal cations per gram of biocompatible material releasably bound thereto.

2. The bioprosthetic article of claim 1, wherein said storage structures collectively have greater than about 10.0 mg metal cation per gram of biocompatible material.

3. The bioprosthetic article of claim 1, wherein said storage structures collectively have greater than about 15.0 mg metal cation per gram of biocompatible material.

4. The bioprosthetic article of claim 1, wherein said metal cations comprise Al⁺³, Fe⁺³, or mixtures thereof.

5. The bioprosthetic article of claim 1, wherein said metal cation comprises Al⁺³ cations.

6. The bioprosthetic article of claim 1, wherein said storage structures comprise ferritin.

7. The bioprosthetic article of claim 1, wherein said biocompatible material comprises mammalian tissue.

8. The bioprosthetic article of claim 7, wherein said natural tissue is selected from the group consisting of heart valves, roots, walls, leaflets, pericardial tissue, cartilage bypass grafts, tendons, ligaments, skin patches, blood vessels and umbilical tissue.

9. The bioprosthetic article of claim 1, wherein said biocompatible material comprises a tissue engineered material.

10. The bioprosthetic article of claim 1, wherein said biocompatible material comprises porcine heart valves or portions thereof.

11. The bioprosthetic article of claim 1, wherein said biocompatible material comprises bovine pericardium.

21. The bioprosthetic article of claim 1 wherein said exogenous storage structure comprises a metal binding protein.

23. The bioprosthetic article of claim 1 wherein said exogenous storage structure is selected from the group consisting of ferritin, transferrin, hemoglobin, metalothien, myoglobin, ceruloplasmin, hemocyanin, isoferritin, and modified proteins with added bifunctional chelators.

12. A bioprosthetic article comprising natural tissue and a plurality of exogenous storage structures that are bound to said natural tissue by covalent bonds, antibody-antigen associations, specific binding protein-receptor associations or enzyme-substrate associations, said storage structures comprising natural macromolecules selected from the group consisting of proteins, carbohydrates and nucleic acids that are in addition or as an alternative to any naturally occurring structures, said storage structures having a quantity of calcification inhibitors releasably bound thereto, and said natural tissue having calcium deposition reduced by greater than about 95 percent relative to equivalent natural tissue without said bound exogenous storage structures after approximately two months of subcutaneous implantation within a mammal.

13. The bioprosthetic article of claim 12, wherein said natural macromolecule comprises ferritin.

14. The bioprosthetic article of claim 13, wherein said calcification inhibitor comprises Al⁺³ cations.

15. The bioprosthetic article of claim 12, wherein said biocompatible material comprises porcine heart valves or portions thereof.

22. The bioprosthetic article of claim 12 wherein said exogenous storage structure comprises a metal binding protein.

24. The bioprosthetic article of claim 12 wherein said exogenous storage structure is selected from the group consisting of ferritin, transferrin, hemoglobin, metalothien, myoglobin, ceruloplasmin, hemocyanin, isoferritin, and modified proteins with added bifunctional chelators.

16. A method of producing a bioprosthetic article comprising the step of binding ferritin to natural tissue, where said ferritin is loaded with calcification inhibiting metal cations such that there are at least 0.5 mg of metal cations per gram of said natural tissue.

17. The method of claim 16, wherein said metal cations comprise Al⁺³ cations.

18. The method of claim 16, wherein said binding is accomplished by covalent or noncovalent bonding of said ferritin to said natural tissue.

19. The method of claim 18, wherein said bonding is performed by contacting said loaded ferritin and said natural tissue with a solution comprising glutaraldehyde.

20. The method of claim 18, wherein said bonding is performed by forming antibody-antigen linkages.